drugset / Trial / NCT06157151
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Timeline
- Start
- 2025-11-11
- Primary completion
- 2026-11-11
- Completion
- 2030-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRGN-2009 | Vaccine | 5e+11 unknown | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |